drugset
drugset / Trial / NCT04706468

To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection

NCT04706468 ↗

Phase 2 Completed 202 enrolled TaiGen Biotechnology Co., Ltd. R&G Pharma Studies Co.,Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the antiviral effect of TG-1000 compared with placebo in adult patients with acute uncomplicated influenza virus infection.

Timeline

Start
2020-12-15
Primary completion
2022-02-15
Completion
2022-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject TG-1000 Unknown 40 mg Oral
Subject TG-1000 Unknown 80 mg Oral

Indications

influenza